Cargando…

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain

BACKGROUND: The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B(2) receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) attacks. Our goal was to assess disease characteristics and icatibant treatment outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guilarte, Mar, Sala-Cunill, Anna, Baeza, María Luisa, Cabañas, Rosario, Hernández, María Dolores, Ibañez, Ethel, de Larramendi, Carlos Hernando, Lleonart, Ramon, Lobera, Teófilo, Marqués, Luis, de San Pedro, Blanca Sáenz, Botha, Jaco, Andresen, Irmgard, Caballero, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715569/ https://www.ncbi.nlm.nih.gov/pubmed/34965883 http://dx.doi.org/10.1186/s13223-021-00641-3

Ejemplares similares

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
por: Blasco, Antonio J, et al.
Publicado: (2013)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema
por: Chung, Arthur G, et al.
Publicado: (2010)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
por: Siani, Maria Concetta, et al.
Publicado: (2012)

87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study
por: Campos, Regis Albuquerque, et al.
Publicado: (2014)

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II
por: Floccard, Bernard, et al.
Publicado: (2012)

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant
por: Bouillet, Laurence, et al.
Publicado: (2017)

Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
por: Crooks, Neil H., et al.
Publicado: (2014)

Treatment of angiotensin-converting enzyme inhibitor related angioedema with icatibant
por: Ho, Peter, et al.
Publicado: (2014)

Could it be hereditary angioedema?—Perspectives from different medical specialties
por: Magerl, Markus, et al.
Publicado: (2023)

454 Efficacy of Icatibant Versus Fresh Frozen Plasma for Attacks of Hereditary Angioedema: Analysis of Indivudual Symptoms by Attack Site
por: Lara, Alicia, et al.
Publicado: (2012)

Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
por: Santucci, Stephanie, et al.
Publicado: (2014)

A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant
por: Bas, M, et al.
Publicado: (2006)

Management of hereditary angioedema in pregnant women: a review
por: Caballero, Teresa, et al.
Publicado: (2014)

Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema in Intubated Patients: Case Series and Literature Review
por: Yeung, Erin K., et al.
Publicado: (2018)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

165 Early Versus Delayed Treatment of Swelling Attacks with Icatibant, a Bradykinin 2 Receptor Antagonist in Patients With Hereditary Angioedema due to C1-INH Deficiency
por: Bork, Konrad, et al.
Publicado: (2012)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_d5858e1bn7ptthb4q8nkpgrqhr